Why the study?
Many patients experience myocardial ischaemia without obstructive epicardial coronary artery disease, highlighting the need to clarify the pathophysiology, risk factors, and clinical consequences of coronary microvascular dysfunction.
This ESC position paper emphasizes the critical role of coronary microvascular dysfunction in myocardial ischemia and other cardiac pathologies, advocating for early detection and targeted interventions.
Answers are grounded in this paper and cite their sources.
Integrates CMD assessment into ischemia workup without obstructive CAD; extends therapeutic targets to microvascular dysfunction in HF and hypertrophy.
Although myocardial ischaemia usually manifests as a consequence of atherosclerosis-dependent obstructive epicardial coronary artery disease, a significant percentage of patients suffer ischaemic events in the absence of epicardial coronary artery obstruction. Experimental and clinical evidence highlight the abnormalities of the coronary microcirculation as a main cause of myocardial ischaemia in patients with 'normal or near normal' coronary arteries on angiography. Coronary microvascular disturbances have been associated with early stages of atherosclerosis even prior to any angiographic evidence of epicardial coronary stenosis, as well as to other cardiac pathologies such as myocardial hypertrophy and heart failure. The main objectives of the manuscript are (i) to provide updated evidence in our current understanding of the pathophysiological consequences of microvascular dysfunction in the heart; (ii) to report on the current knowledge on the relevance of cardiovascular risk factors and comorbid conditions for microcirculatory dysfunction; and (iii) to evidence the relevance of the clinical consequences of microvascular dysfunction. Highlighting the clinical importance of coronary microvascular dysfunction will open the field for research and the development of novel strategies for intervention will encourage early detection of subclinical disease and will help in the stratification of cardiovascular risk in agreement with the new concept of precision medicine.
No takes yet. Share an insight, caveat, or question.
Padró et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: